Lv4
700 积分 2024-05-08 加入
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
10小时前
已完结
Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study
3个月前
已完结
Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study
3个月前
已关闭
The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China
3个月前
已完结
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
4个月前
已完结
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS
4个月前
已完结
Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view
4个月前
已关闭
Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment
4个月前
已完结
Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era
4个月前
已完结
Renal failure in multiple myeloma: something new on the horizon
4个月前
已完结
皖公网安备34019202002308
